When pharmaceutical companies seek approval of a drug or vaccine from the Food and Drug Administration, general counsel and law firms generally play a limited, but critical, role in developing the strategy to present to the agency.

Such FDA talks are headline news now, amid the continued rollout of vaccines and treatments for COVID-19. Just in the last week, the FDA authorized additional vaccine doses made by Moderna and Pfizer for immunocompromised individuals.